



**Our mission is to improve
the lives of patients suffering from
immunological diseases**

Ukrainian Association for Clinical Research, 29 June 2023

Jenny Sundqvist, CEO, InDex Pharmaceuticals

Dr Eva Arlander, CDO, InDex Pharmaceuticals

Forward looking statements

This presentation contains certain forward-looking statements reflecting the Company's current view of future events and financial and operational performance. Such forward looking statements are associated with both known and unknown risks and circumstances outside the Company's control. All statements in this presentation other than statements of historical or current facts or circumstances are forward-looking statements. Forward looking statements are made in several sections of the presentation and can be identified by the use of terms or expressions such as "may", "could", "should", "anticipated", "estimated", "expected", "likely", "forecasted", "plans to", "aims to", or conjugations of such terms or similar terms. The forward looking statements only apply as of the date of this presentation. The Company has no intent or obligation to publish updated forward looking statements or any other information contained in this presentation based on new information, future events, etc. other than required by applicable law, regulation or regulatory framework.

Our mission is to improve the lives of patients suffering from immunological diseases

- Founded: 2000. Based: Stockholm, Sweden.
Origins: Karolinska Institutet
- Listed on the Nasdaq First North Growth Market Stockholm
- Main shareholders: Linc, HBM, 4th AP Fund, SEB
- Broad portfolio of pre-clinical stage assets from proprietary technology platform (DIMS)
- **Main asset: cobitolimod for ulcerative colitis (in phase III)**

Highly knowledgeable team with proven track records

Board of Directors (6 members)

Long & extensive experience of drug development/finance from senior positions in pharmaceutical industry



InDex organization

Agile team of 18 persons with a mix of full-time employees and specialized consultants

Highly diverse team

- 67% women in both BoD and InDex team
- 7 different national origins
- 1/3 have PhDs in relevant research areas




Ulcerative colitis (UC) is a serious and chronic inflammatory bowel disease

- Disabling symptoms
- Elevated risk of colon cancer
- Low quality of life
- Periodic flares
- Diagnosed between 15 and 30 years old
- No cure




Felicia
suffers from ulcerative colitis


Ulcerative colitis is a disease with high unmet medical need




Only help a small fraction of patients:
limited efficacy and tolerance development



Can cause serious side effects



Act on the whole body, not only the colon



Need for safer therapies and new MoA

There are safety concerns with current drug classes



TNF- α inhibitors



Integrin inhibitors



JAK inhibitors



IL12/IL23 inhibitors



S1PR modulators

Infections

Skin cancers

Death

Our aim with cobitolimod = competitive efficacy & superior safety



TLR-9



TNF- α inhibitors



Integrin inhibitors



JAK inhibitors



IL12/IL23 inhibitors




S1PR modulators



No known drug related SAEs


Drug related SAEs

Our Phase III program consists of 3 studies




The global program is up and running

- Approved in all 30 countries
- 440 patients in >200 clinics
- Proud to be running in Ukraine




Patients in focus – an endoscopic view

Normal mucosa



Mild inflammation

Moderate inflammation



Severe inflammation

Expectations and motivations



- More treatment options
- Long-term effects
- Safety



- Few options available
- Less systemic effects
- Patient safety

InDex and Ukraine

- Very good experience from Phase 2
- Phase 3 study was initiated end 2021. Russia and Ukraine were included
- March 2022: decision taken to stop in both RUS and UKR
- Decision revisited during summer 2022
- Thorough analysis together with Parexel and decision to restart in UKR in September
- Technical equipment, study drug shipment, lab samples
- Statistical analysis



Our experience to date

Logistics & study conduct

- No interruptions so far. Standard couriers are used
- No interruptions due to technology
- Regulatory and ethical approvals received in a timely manner



Our experience to date (cont.)

Sites

- Investigators are very dedicated and actively contributing to the study
- We will increase from 6 sites up to 10
- Sites have special mitigation plan enforced to mitigate power or internet failure (power generators and power banks are available)
- If necessary, sites are prepared to evacuate to another site
- In general, a very limited number of trials are running



THANK YOU!